PMID: 15795548Mar 30, 2005Paper

Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy

Clinical Neuropharmacology
Vladimir LernerChanoch Miodownik


Despite the effectiveness of antipsychotic medications in treatment of schizophrenia, about 30% of patients who receive an adequate treatment have significant persisting symptoms. The problem of treatment-resistant psychosis is an important and difficult one. The aim of this study was to retrospectively evaluate the efficacy and safety of amisulpride augmentation in treatment-resistant schizophrenic patients. To the best of our knowledge, this is the first report about resistant schizophrenic and schizoaffective patients treated with the combinations of risperidone and amisulpride and ziprasidone and amisulpride. Data were collected from patient records. A total of 15 resistant schizophrenic patients (7 men, 8 women, 54.0 +/- 16.9 years old) were included in the study. Before addition of amisulpride, the patients were treated with monotherapy by atypical neuroleptics (clozapine, olanzapine, risperidone, or ziprasidone). The mean amisulpride dose was 693.3 +/- 279.6 mg/d. The mental state of 12 (80%) patients treated with combination was improved. Three (20%) patients showed no change in their mental state. Only 2 patients treated with a combination of risperidone and amisulpride had mild side effects. The results are preliminar...Continue Reading


Mar 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·D F LevinsonG M Simpson
Feb 1, 1996·The Australian and New Zealand Journal of Psychiatry·C Pantelis, T R Barnes
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G BondolfiH Dufour
Jan 1, 1997·International Clinical Psychopharmacology·J P LépineA Tylee
May 1, 1997·International Clinical Psychopharmacology·W Rein, S Turjanski
May 1, 1997·International Clinical Psychopharmacology·B ScattonH Schoemaker
Jan 20, 1998·The American Journal of Psychiatry·M P Freeman, A L Stoll
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
Aug 22, 2001·European Journal of Pharmacology·A W SchmidtS H Zorn
Feb 20, 2003·The Journal of Clinical Psychiatry·Katie A BuschDouglas G Jacobs
Nov 25, 2003·The Journal of Clinical Psychiatry·Robert E McCueLeonel Urcuyo
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vladimir LernerRael D Strous
Feb 19, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Mathias ZinkJohannes Thome
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N BergemannA Frick
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
May 4, 2004·The American Journal of Psychiatry·Marcus W AgelinkIsmail Ak
May 4, 2004·The American Journal of Psychiatry·David Israeli, Joseph Zohar

❮ Previous
Next ❯


Sep 13, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
May 2, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fábio Lopes Rocha, Cláudia Hara
Mar 15, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·V P KontaxakisC R Soldatos
Aug 2, 2008·Expert Opinion on Pharmacotherapy·Martin LambertChristian G Huber
Nov 10, 2006·Journal of Psychopharmacology·Jenifer Chan, Melinda Sweeting
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Dec 4, 2008·Clinical Neuropharmacology·Ivan Lerma-CarrilloEnrique Baca-García
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Dec 18, 2019·The Cochrane Database of Systematic Reviews·Philippa DaviesNicola Wiles
Oct 22, 2005·Clinical Neuropharmacology·Marc ZiegenbeinHeike E Kuenzel
Jan 29, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Seung-Gul KangSeong-Jin Cho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here